- Home
- RCS vs TARA Comparison
RCS vs TARA Comparison
Compare RCS & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | TARA |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.8M | 268.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | RCS | TARA |
|---|---|---|
| Price | $5.20 | $5.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $21.67 |
| AVG Volume (30 Days) | 156.8K | ★ 632.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.09 | $2.77 |
| 52 Week High | $8.00 | $7.82 |
Technical Indicators
Market Signals| Indicator | RCS | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 45.77 |
| Support Level | $5.09 | $4.92 |
| Resistance Level | $5.81 | $5.39 |
| Average True Range (ATR) | 0.18 | 0.31 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 25.48 | 60.14 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).